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ABSTRACT
Hearing loss is a major problem in our society with more than 5 % of the 
population world-wide suffering from disabling hearing loss according to the 
WHO. There are many endocrine syndromes associated with hearing loss. In 
both Turner syndrome and Pendred syndrome hearing loss is a prominent 
feature often leading to a need for hearing rehabilitation with hearing aids 
or cochlear implants. Hormonal treatment might also affect the inner ear 
directly and studies have shown a negative effect on hearing by progeste-
rone treatment.
The overall aim of this thesis is to enlighten the close connection between 
hearing and endocrinology both directly via hormonal effects on the inner 
ear and indirectly by which endocrine syndromes have an impact on both 
hearing and endocrine target organs.
Studies I and II explore the audiological features in young women with 
Turner syndrome and the effect of hormonal treatment. Sensorineural 
hearing loss is common with high-frequency hearing loss and mid-frequency 
dip being the configurations most often seen. The mild to severe hearing 
loss concentrated to the high- and mid-frequencies leads to reduced speech 
perception which leads to the necessity of hearing rehabilitation with 
hearing aids. No effect on hearing by the hormone replacement therapy with 
estrogen was seen but a negative effect on high-frequency hearing, attri-
buted to the growth hormone treatment, was found.
Study III investigates the presence of progesterone receptors in the inner ear 
which could explain a direct negative effect on hearing by progesterone con-
taining hormone replacement therapy. No nuclear progesterone receptors 
were found according to the results of the immunohistochemistry, in rat and 
human, and by PCR and Western blot in rat. Therefore, direct nuclear effect 
seems unlikely.
Study IV investigates the natural hearing history and outcome after cochlear 
implantation in children with severe hearing loss due to Pendred syn- 
drome or DFNB4 having LVAS and/or IP2-malformation. A severe to profound 
hearing loss is seen, often with an early onset, but progressive hearing loss 
is not rare. The speech and language tests show low results in expressive 
vocabulary and pragmatic skills but normal results in receptive vocabu- 
lary. Additional symptoms are vertigo, fluctuating hearing, motor problems, 
concentration deficits and sleeping disturbances.
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In conclusion, hearing impairment is common and linked to several endo-
crine syndromes including Turner syndrome and Pendred syndrome. In both 
syndromes the hormonal and genetic impact can lead to severe hearing 
impairment though the risk for congenital severe hearing loss is present 
only in Pendred syndrome. An early rehabilitation with hearing aids or 
cochlear implants in regard to the hearing deficit is necessary to prevent 
social isolation and to ensure speech development and speech perception. 
Hormonal treatment might interfere with hearing but no direct nuclear effect 
of progesterone on the inner ear was found. 
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PREFACE
If you had a slight hearing loss, between 26-40 dB, you would have 
trouble hearing soft speech from a distance or speech in a background 
noise. If you had a moderate hearing loss, between 41-60 dB, hearing 
regular speech, even at a close distance, would be problematic. With 
a severe hearing loss between 61-80 dB, you may only hear very loud 
speech and surrounding noise, as loud as a fire siren or a door slam. 
Most conversational speech would not be heard. With a profound 
hearing loss, above 80 dB, you may only perceive loud sounds and 
vibrations.
(Adapted from WHO’s grading of hearing loss).
Communication is important for all animals, including humans. The 
main communication mode, speech, is dependent on our ability 
to hear. We use our hearing continuously and for a wide variety of 
purposes. It is the sound of our parents’ voices that calms us as 
babies in destress, the hearing that is necessary for listening to bedtime 
stories, exchanging thoughts, feelings and ideas with friends and 
colleagues as well as alerting us of danger, like detecting the sound 
of falling branches from a tree or the fire alarm. Most people in the 
world are using spoken language for communication but about 70 
million deaf people worldwide have sign language as their first langu-
age (https://wfdeaf.org/faq/, 170610).
Hearing impairment is a major problem in our society and according to 
WHO (http://www.who.int/mediacentre/factsheets/fs300/en/ 170622) 
over 5% of the population in the world suffer from a disabling hearing 
loss. In Sweden, 6.0 % of men and 2.9 % of women between the ages 
of 18-50 years have a hearing loss, these percentages do not include 
the elderly with their higher incidence of hearing loss (1).
16
Åsa Bonnard 2017
17
Hormon effect on the inner ear: two endocrine syndromes
BACKGROUND
Anatomy and physiology of the ear
The ear transforms airborne soundwaves into electrical signals in three dif-
ferent steps. The soundwaves in the air are captured by the auricle (a part of 
the external ear) and continues through the auditory canal to the eardrum, 
the tympanic membrane. The tympanic membrane and the three auditory 
ossicles, the malleus, incus and stapes, compose the middle ear. The fun-
ction of the middle ear is to amplify the sound by about 60 dB. By vibrating 
the tympanic membrane and the three middle ear bones the soundwaves 
from the air are transformed into a mechanical force further transmitted via 
the stapes footplate in the oval window to form pressure-waves in the fluid 
in the inner ear, the cochlea (figure 1).
The cochlea is a snailshell-like structure and normally makes two and a half 
turns in humans. It is divided into three channels: the Scala vestibuli, Scala 
media and Scala tympani, divided by the Reissners’ membrane and the basal 
membrane. The pressure wave transmitted by the stapes footplate will travel 
inside the Scala vestibuli from the base of the cochlea to the apex and then 
back again trough the Scala tympani. The exceeding force will be eliminated 
Figure 1: Schematic image of the human ear divided in external, middle and inner parts. 
Republished with the kind permission of Rusana Bark.
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through the round window. The organ of Corti is located in the Scala me-
dia, which is situated between the Scala vestibule and tympani. This is the 
sensory organ of hearing where the pressure wave is transformed into an 
electrical signal. The organ of Corti contains one row of inner hair cells and 
three rows of outer hair cells covered by the tectorial membrane, where the 
stereocilia are embedded. When the pressure wave in the Scala vestibuli mo-
ves the basilar membrane, the hairs, stereocilia, on top of the hair cells will 
bend activating a cascade of events leading to the activation of the cochlear 
nerve (figure 2).
Figure 2: A drawing of the human inner ear anatomy with a mid-modiolar section (a) 
and an enlarged spiral canal with the three Scala, vestibuli, media and tympani and the 
spiral ganglion (b). The sensory organ of hearing, the Organ of Corti, is situated in the 
Scala media with its inner and outer hair cells (IHC and OHC) (c). Republished with the 
kind permission of Rusana Bark.
Depending on the frequency of the pressure wave, a specific area along the 
membrane will have a maximal reaction to the stimuli, i.e. the basilar mem-
brane is tonotopic (2). The high frequencies will cause a maximal reaction in 
the basal turn of the cochlea and the low frequencies in the apex. In order 
for the hair cell to be able to release this electrical impulse, the ionic content 
of the surrounding liquids is essential. In the Scala media the endolymph is 
rich in potassium and the perilymph-containing Scala vestibule and tympani 
are rich in sodium creating an electrochemical gradient. When the stereocilia 
19
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deflect, mechanically gated ion-channels open and positively charged ions 
(potassium and calcium) flow into the cell from the surrounding endolymph 
and a depolarization follows. This opens voltage-gated calcium channels and 
the entry of calcium ions triggers the release of neurotransmitters that will 
activate the nerve. The positive ions are then transferred to the perilymph by 
the electrochemical gradient. 
The spiral ganglion nerve threads, situated in the modiolus (middle) of the 
cochlea, comprise the cochlear nerve which connects to the cochlear nuclei 
in the brainstem. Nerve fibers continue through the brainstem, mid-brain 
and thalamus to the primary auditory cortex in the temporal region. The 
afferent system crosses over in the brainstem thus making the auditory 
input from one ear stimulate the cortex-region on both sides of the brain 
(figure 3).
Figure 3: The central auditory pathways from the cochlea, via the cochlear nerve, the 
brainstem (cochlear nucleus), the pons (superior olivary nucleus), the mid-brain (infe-
rior colliculus), the thalamus (medial geniculate body) and to the auditory cortex in the 
temporal lobe. The figure is showing the bilateral stimulation of the auditory cortex by 
the cross-over at the brainstem level. Republished with the kind permission of Rusana 
Bark.
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Inner ear development and malformation
The inner ear is developed from the otic placodes that begin to be visualized 
at day 22 on the outside of the embryo. At the fourth embryonal week it has 
invaginated and formed an otic cyst that will become the future cochlea and 
vestibular organ. At 8 weeks the cochlea has its final 2.5 turns and during 
week 9-12 the organ of Corti is fully developed. Parallel to this, the vestibu-
lo-cochlear nerve develops and a connection between the cochlea and the 
brainstem is established at 9 weeks. During the second trimester, the organ 
of Corti matures and auditory connections between the brainstem and the 
brain begin to develop (3, 4). Already by the end of the second trimester, 
around week 22, the fetus starts to hear. Interruptions in these processes 
lead to different malformation depending on the stage of development and 
genesis. Sennaroglu et al presented a new classification for vestibulo-cochle-
ar malformations in 2002 based on the findings from computer tomography 
and magnetic resonance imaging in relation to the embryonic development 
(4). They divided the malformations into different groups depending on the 
time of developmental arrest. These malformations ranged from a complete 
lack of cochlea and vestibular organs to an almost normal cochlea with only 
an incomplete partition of the last turn, named an incomplete partition type 
2 (IP2).
Incomplete Partition type 2 and Large Vestibular Aqueduct Syndrome
In IP2-malformation the inner ear is normal or slightly hypoplastic with a 
fused apex resulting in only 1.5 turns of the cochlea. This represents a de-
velopmental arrest in the seventh fetal week. There are different degrees 
of modiolar dysplasia and a histological study showed a reduced number 
of cells in the spiral ganglion with extensive inter-individual variation which 
might affect the hearing (5). A combination of a large vestibular aqueduct 
(Large Vestibular Aqueduct Syndrome, LVAS) and IP2 is common but both IP2 
and LVAS can occur in isolation. These malformations can be seen in seve-
ral syndromes such as Pendred, branchio-oto-renal, CHARGE and DiGeorge’s 
syndromes as well as in a non-syndromic deafness (DNFB4). This autosomal 
recessive inherited malformation has in approximately 50% of the cases 
homo- or heterozygote mutations in the SLC26A4 gene, however a combina-
tion including a mutation in FOXI1 or KCNJ10 has also been found (6-8).
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Figure 4: MRI of the skull base and the inner ears showing scalar asymmetry 
(thick white arrow), large vestibular aqueduct, LVAS (thin white arrow) and 
enlarged endolymphatic sac (circle).
Endocrine interaction with the auditory system
There are many endocrine disorders associated with hearing loss. Among 
these are a high frequency sensorineural hearing loss linked to IGF-1 defi-
ciency, an increased frequency of sensorineural hearing loss in acromegaly, 
hypoparathyroidism and sensorineural deafness in Barakat syndrome and 
congenital hypothyroidism (endemic cretinism) composed of dwarfism and 
sensorineural hearing loss (9). The mechanisms differ from genetic muta-
tions interfering with the fetal development resulting in inner ear malforma-
tion to ongoing processes due to hormonal insufficiency leading to an early 
hearing loss. 
Turner syndrome
Turner syndrome is the most common sex-chromosome disorder in women 
and occurs in one out of 2500 live-born girls (10). Girls with Turner syndrome 
are born with a total or partial loss of one female sex-chromosome which 
leads to an estrogen deficiency due to a lack of or underdeveloped ovaries. 
Short stature (around 142 cm in non-treated), no spontaneous development 
of secondary female phenotypes and infertility are the main characteristics 
of the syndrome (11). There are several karyotypes where 1) 45,X have a 
total loss of one X-chromosome, 2) 46,X,i(Xq) have an isochromosomy of the 
q-arm, as well as 3) a mosaic of normal and Turner-type cells are the three 
most common ones. In the literature, having 45,X or 46,X,i(Xq) karyotype is 
22
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associated with a higher incidence of comorbidities such as congenital heart 
defects, hypertension, osteoporosis, auto-immune diseases, for example 
diabetes mellitus and hypothyroidism, as well as hearing disturbances (10, 
12).
Ear and hearing problems are frequent in women with Turner syndrome and 
have a negative effect on their wellbeing and quality of life (13, 14). Throug-
hout life, different periods of ear and hearing problems can be seen in girls 
and women with Turner syndrome. During childhood, there is a high inci-
dence of otitis media resulting in a conductive hearing loss, frequent tym-
panostomy tube insertions and antibiotic treatment (15-17). Women with 
Turner syndrome also develop a higher incidence of chronic otitis media and 
cholesteatoma over time (18, 19). Sensorineural hearing loss in the form of 
a mid-frequency dip can be present as early as age five and progresses over 
the years (20, 21). A high frequency sensorineural hearing loss that develops 
in early adulthood is often present and this can have a devastating effect 
on the hearing situation for the individual. In such cases, hearing aids are 
often required earlier than in the normal population (12, 22-24). There is an 
increased risk for ear and hearing problems in women with karyotype 45,X 
or 46, X,i(Xq) (12, 16, 25).
Estrogen treatment is used in order to prevent osteoporosis and cardio-
vascular diseases as well as promote puberty. About one third of girls with 
Turner syndrome will start a normal pubertal development but less than 5 
% will have a normal menstruation cycle. Fertility and estrogen treatment 
is begun around the age of 12 (11). The estrogen treatment is induced at 
low doses with pure estrogen and changed for a combination pill including a 
progesterone content depending on the stage of pubertal development. The 
treatment is ended by the time of menopause. 
Historically, anabolic steroids have been the treatment of choice for height 
improvement, but in 1980 the first recombinant growth hormone treatment 
was introduced in Sweden. Today this is the treatment of choice and has 
been shown to be effective with few side-effects according to several studies 
(20, 26-30). In the first studies on growth hormone substitution an increased 
incidence of otitis media was seen, but this could not be confirmed in later 
studies (20, 27). There is however ongoing research on the effect of growth 
hormone and its metabolite IGF-1 on the inner ear, where IGF-1 is shown to 
be crucial for embryonic inner ear development. Girls with a low concentra-
tion of IGF-1 in childhood have a higher risk of sensorineural hearing loss 
(25).
23
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Pendred syndrome
Pendred syndrome is a genetic disorder composed of a triad of symptoms, 
hearing loss, vertigo, and thyroid enlargement (goiter) (31). It has a muta-
tion in the PDS-gene (SLC26A4) responsible for the Pendrin protein involved 
in bicarbonate (HCO3-) transport in the inner ear and kidneys and iodine (I-) 
transport in the thyroid gland (6, 32-34). In Pendred syndrome there is usual-
ly a homozygote mutation with one mutated gene in the genome from both 
parents. A heterozygote mutation (a mutation from only one parent) is more 
frequently accompanied with a non-syndromic hearing loss, DFNB4, where 
the thyroid is not affected. The KCNJ10 gene, known to be affected in some 
patients, is also responsible for an ion-receptor necessary for hair cell depo-
larization (8). FOXI1, a transcriptor-regulating gene, is another known gene 
involved in Pendred syndrome (35). This gene is necessary for the transcrip-
tion of SLC26A4. As mentioned earlier, the specific inner ear malformation, 
IP-2 and LVAS, is seen in individuals with Pendred syndrome (36).
The hearing impairment problem in Pendred syndrome is of sensorineural 
type and ranges from mild to profound (31, 37). A child can be born with 
a profound hearing loss but it can also be progressive and fluctuation in 
hearing is common. In children with fluctuating hearing loss the adjustment 
of hearing aids poses a great problem as does speech and language acqui-
sition due to a non-predictable hearing situation. A fluctuation in hearing 
ability can also be a reason for late identification of hearing loss due to 
variability in results on hearing tests. Head trauma or upper airway infections 
can provoke a worsening in hearing. Vertigo is present in about one third 
of the patients and is often displayed by episodes of vertigo ranging from 
seconds up to days (31, 37, 38). For some individuals, it can be provoked by a 
raised internal pressure in the inner ear as when doing sit-ups or the Valsalva 
maneuver. The thyroid enlargement manifests during the second decade of 
life and is usually euthyroid. Occasionally, thyroid hormone substitution is 
necessary (31, 38).
Hormonal treatment
The girls and women with Turner syndrome, as well as a significant number 
of women world-wide, are treated with combination pills containing estro-
gen and progesterone for a long period of time (contraceptive or hormone 
replacement therapy). There is normally a difference in hearing throughout 
life between women and men where hearing starts to decline in the thir-
ties for men and in the fifties for women. This difference cannot entirely be 
explained by a difference in occupational noise exposure (39, 40). There is 
growing evidence for a protective effect of estrogen on hearing by BDNF, 
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a neuroprotective peptide, responsible for the postponed hearing decline 
in women (41-43). This effect might be dose- and age dependent (44-46). 
There are studies suggesting that menopausal women treated with Hormo-
ne Replacement Therapy (HRT) have a better hearing than the non-treated, 
however the results have been contradictive and some are arguing for a ne-
gative effect of the progesterone part in HRT (47, 48).
Hearing loss
 
There are three main types of peripheral hearing loss, conductive, sensori-
neural and mixed. Conductive hearing loss is due to a disturbed pathway for 
the sound from the ear canal and through the middle ear. Problems inter-
Figure 5: An audiogram showing hearing per frequency (in hertz, Hz) in decibel (dB). The 
grades of hearing loss are shown in different shades of yellow from normal hearing to 
profound hearing loss (HL). Specific environmental sounds and phonemic sounds in the 
Swedish language are shown in regard to the hearing level needed for detection. Publis-
hed in adapted form with the kind permission of Cochlear Nordic AB.
25
Hormon effect on the inner ear: two endocrine syndromes
Figure 6: Types of audiometric configuration with a) high frequency sloping, b) mid-
frequency u-shaped (dip), c) low-frequency rising and d) flat loss.
fering with the inner ear or nerve give rise to sensorineural hearing loss. The 
combination of these two is called a mixed hearing loss. As described in the 
preface, hearing loss can also be divided in regard to degree from mild to 
profound (figure 5) as well as by configuration (high-frequency sloping, mid-
frequency u-shaped, low-frequency rising, flat loss) (figure 6).
 
Treatment for hearing loss
There are different types of treatment for hearing loss depending on the 
type and degree. Surgery with ossiculoplasty or middle ear implants can be 
efficient for mild to moderate conductive or mixed hearing loss. In other 
cases, a hearing aid is a better solution. For severe to profound hearing loss 
a cochlear implant is the treatment of choice. If the cochlea or the cochlear 
nerve is missing a brainstem implant is the prefered solution.
Hearing aids
The most common treatment for hearing loss today is hearing aids. It is used 
in mild to severe hearing loss and works as a sound amplifier, resembling 
the function of the middle ear. It collects the sound with an external micro-
phone, enhances the signal and projects it into the ear canal. For this system 
to work, the ear must have enough hair cells remaining in the inner ear in 
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order to create an electric signal to the brain. When there is a lack of hair 
cells the possibility to hear will decrease in general, but the lack of hair cells 
can also affect the quality of the sound making it harder to interpret words. 
For people with severe to profound hearing loss a cochlear implant might be 
the treatment of choice.
Cochlear implant
A cochlear implant is a hearing aid that transduces sound collected by an 
outer microphone into electrical impulses, through the utilization of a pro-
cessor. These impulses are magnetically transferred through the skin and in 
to the inner receiver. A thin electrode is placed in the Scala tympani in the 
cochlea where the neurons are stimulated directly. This permits sound to by-
pass non-functioning hair cells in the inner ear and send the stimuli directly 
to the nerve. The tonotopic function of the inner ear helps the patients to 
distinguish between different frequencies (figure 7). The cochlear implant 
was invented independently by three research groups in Australia, Austria 
and the USA (49). The first cochlear implant had a single channel for stimula-
tion and only provided the possibility of hearing sounds. Today the implants 
have between 12-22 channels and the great majority of patients use their 
implants for speech perception.
 
 
Figure 7: A cochlear implant with its outer processor transmitting the sound via the mag-
net through the skin to the implant on the inner side. The electrode passes via the mas-
toid, middle ear and through the round window in to the cochlea. Reprinted with kind 
permission from MedEl Nordic AB.
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AIMS
The overall aim of this thesis is to enlighten the close connection between 
hearing and endocrinology both directly via hormonal effects on the inner 
ear and indirectly where endocrine syndromes have an influence on both 
hearing and the endocrine target organs.
Specific aims:
1. To describe the audiometric features in young women with Turner 
syndrome and the extent of hearing rehabilitation with hearing aids 
(Study I).
2. To investigate the effect of estrogen substitution, growth hormone and 
anabolic steroid treatment on hearing in young women with Turner 
syndrome. This research has been conducted using two cohorts with 
different treatment schemes (Study II).
3. To investigate a possible direct effect of progesterone via progesterone 
receptors in the inner ear (Study III).
4. To investigate the natural history of the development of hearing loss 
and vertigo in children and young adults with Pendred syndrome and 
DFNB4 and to describe the results on hearing, language and social 
skills development after cochlear implantation in these individuals 
 (Study IV).
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SUBJECTS AND METHODS
Subjects and design
Studies I and II
Sixty-four women with Turner syndrome between the ages of 25-38 were 
included from the Turner center at Karolinska University Hospital. The wo-
men were recruited from two time-frames and were born between 1973 
and 1985 (n=35, mean age: 32.4 years) in the recent cohort, and from 1954 
to 1967 (n=29, mean age: 32.7 years) in the historic cohort. The two cohorts 
were chosen to compare the effects of estrogen substitution, growth hor-
mone, and anabolic steroid treatment before and after the introduction of a 
new treatment guideline 1980 (study II). In study I all subjects were pooled 
to describe the audiological features in this age-span of young women with 
Turner syndrome. 
All subjects performed or had performed a pure-tone audiometry with 
air- and bone conduction thresholds (0.125-8 kHz and 0.5-4 kHz respec- 
tively). The type and degree of hearing loss as well as type of audiometric 
configuration was identified and the degree was compared to a Swedish 
cohort comprised of normal hearing individuals. Information about estro-
gen, growth hormone and anabolic steroid treatment, karyotype, otitis 
proneness, ear surgery, spontaneous puberty, smoking, family history of 
hearing loss, treatment with ototoxic medication and the use of hearing aids 
were collected from the patients’ charts. These studies were approved by 
the regional ethics committee (No 2012-374-311).
Study III
In total sixteen inner ears from 3-12-month-old, male and female Sprague 
Dawley rats and two 60 years old postmortem donated human inner ears 
were used in this study. All rats were bought from the Jackson Laboratory 
and were housed locally in a controlled environment with food and water 
ad libitum. The rats were euthanized after being deeply anaesthetized with 
Xylazine, Ketaminol and thereafter carbon monoxide was used. The inner 
ears were removed and, depending on the method of investigation, decal-
cified, paraffin-embedded and sectioned for immunohistochemistry, dissec-
ted from surrounding bone for PCR or placed in an ice-cold solution of com-
plete protease inhibitor for the Western blot. All animal experiments were 
approved by the Animal Care Committee in Stockholm, Sweden (N359/02, 
N370/04, N200/5 and N157/09).
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The two human inner ear specimens were donated to us. Both cochleae were 
from 60-year old females with no previous history of hearing disease or hea-
ring loss. The first cochlea was harvested post mortem in Austria and used 
for the immunohistochemistry studies. The second cochlea was harvested 
during skull base surgery for Schwannoma and was prepared and cryosectio-
ned in Uppsala to be used for immunofluorescence studies. The use of the 
specimens was approved by local ethics committees in Austria and Uppsala 
(no.99398, 22/9 1999, no.C254/4, no. C45/7 2007).
Study IV
Twenty-nine individuals, aged between 1.8-25.2 years, diagnosed with 
LVAS and/or IP2 inner ear malformation, and implanted with unilateral or 
bilateral cochlear implants as children participated in the study. Five individu-
als had genetically diagnosed Pendred syndrome. The hearing history could be 
divided in three distinct subgroups: (1) severe to profound congenital 
deafness and early surgery (before the age of 2 years), (2) late implanted con-
genitally deaf children or hearing aid users with moderate to severe hearing 
loss, but slow progress in speech development and (3) progressive deafness 
with hearing aids preoperatively with a history of good hearing. They all partici- 
pated in a full day of investigations including hearing tests, speech and 
language tests, vestibular and balance tests, and a structured medical interview. 
Questionnaires were distributed to parents and teachers regarding social 
and cognitive skills. Retrospective information regarding surgery, electrode 
use and adverse effects was collected from the patients’ charts. MRI and/
or CT scans were reviewed and systematically analyzed. This study was 
approved by the regional ethics committee (2014/2068-31/2).
Audiology
Pure tone audiometry and audiometric features
In order to establish the hearing level of the quietest sound detectable for an 
individual the normal “hearing test”, pure tone audiometry, is performed in a 
sound proof room. Adults and older children listen to a sound in headphones 
and push a button when the sound is detected. For the younger children, a 
behavioral observation audiometry is performed when the audiologist de-
tects a behavioral change in the child as a reaction to a given sound. Air con-
duction and bone conduction audiometry for the frequencies 0.125-8 kHz 
and 0.250-4 kHz respectively was performed in studies I, II and IV. Pure tone 
average (PTA4) were calculated as the mean of 0.500, 1, 2 and 4 kHz and was 
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used to determine the degree of hearing loss according to the HEAR-classifi-
cation  (figure 5, table 6) (50). In studies I and II, type of hearing was classified 
as: normal hearing, sensorineural-, conductive- or mixed hearing loss. Nor-
mal hearing was classified as a hearing level per frequency better than 20dB, 
a hearing level per frequency 20 dB or worse with a difference between bone 
and air conduction of less than 15 dB was classified as sensorineural hearing 
loss and a difference between bone and air conduction of 15 dB or more 
with a normal bone conduction was classified as conductive hearing loss. A 
mixed hearing loss had a difference of 15 dB or worse between air and bone 
conduction with a bone conduction worse than 20 dB. The classification of 
hearing loss was divided into five different subtypes according to the modi-
fied classification by Hederstierna et al (47). The types are high-frequency 
sloping, mid-frequency u-shaped, flat loss and low-frequency rising (figure 
5).
Definitions
Grade of hearing loss according to HEAR
    Normal hearing <20 dB
    Mild hearing loss 20-<40 dB
    Moderate hearing loss 40-<70 dB
    Severe hearing loss 70-<95 dB
    Profound hearing loss 95 dB and above
Configuration
    High-frequency sloping The average threshold at 0.5 and 1 kHz is ≥15 
dB better than the average of the thresholds 
at 4, 6 and 8 kHz
    Mid-frequency u-shaped One or more adjacent thresholds between 
0.75 and 2 kHz are ≥20 dB poorer relative 
to any thresholds at lower frequencies and 
≥15 dB poorer relative to threshold at higher 
frequencies
    Flat loss Thresholds across frequencies 0.25-8 kHz do 
not vary more than 15 dB from each other
    Low-frequency rising The average of the thresholds at 0.25 and 0.5 
is ≥15 dB poorer than the average of the th-
resholds at 4, 6 and 8 kHz
Table 1: Definitions of the grade of hearing loss according to HEAR (50) and the different 
configurations in accordance to Hederstierna et al 2007 (47).
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Speech Audiometry and Adaptive HINT
Children and adults with cochlear implants usually have difficulty hearing in 
noisy environments (discrimination). In order to assess the level of discrimi-
nation three different methods were used in study IV: speech audiometry in 
quiet and noise and adaptive HINT (Hearing In Noise Test). Hearing in noise 
has a higher demand on the overall auditory system due to the activation 
of both primary auditory cortex and other auditory associated areas in the 
brain. Loss of function in the auditory associated areas e.g. in aging or hea-
ring impairment will hamper the hearing in noise (51).
The participants in study IV performed speech audiometry in quiet from the 
age of four, where they listened to lists of twenty-five monosyllabic phonetic 
balanced words and were asked to repeat what they heard. The test was 
then performed in background noise that had a fixed signal to noise ratio of 
0 dB (52).  The speech and noise test was performed from the age of six. The 
result is presented as a percentage of correct answers. In the adaptive HINT 
the participants listened to lists of short phrases in which the signal to noise 
ratio was changed in regard to correct or false answer (53). The result is the 
level of background noise in dB where the individual can repeat 50% of phrases 
correctly resulting in a test without an upper or lower limit.
Sound-localization
Sound-localization is important for directional hearing as well as hearing in 
noise. Persons with hearing impairment have difficulty with both. A better 
result has been shown with bilateral cochlear implants when comparing with 
a unilateral listening situation (52). The patients’ age at time of implanta-
tion and the time between implantation in the two ears also play key roles 
(52, 54). In this test, used in study IV, the individual were placed in front of 
five loudspeakers covering 180 degrees with an inter-loudspeaker spacing 
of 45 degrees. The patient utilized their best-hearing solution (e.g. bilate-
ral cochlear implants; bimodal hearing aid and cochlear implant; unilateral 
cochlear implant) (52). A sound was presented and the individual was in-
structed to indicate the source of the sound. The sounds were given in a 
random order from the multiple loudspeakers, for ten repetitions. An error 
index (EI) was calculated based on the sum of all azimuth errors in the test. 
This resulted in a value between 0 and 1 where 0 is a perfect match and 1 
corresponds to complete guessing. A result >0.540 was regarded better than 
chance. This test was performed from the age of four.
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Laboratory tests
Sprague Dawley rats were used for all laboratory work, a model well used for 
mapping receptors in the inner ear.
Immunohistochemistry
This method used in study III is employed to map the existence, locali- 
zation, and distribution of receptors in tissues. A standard immunohisto-
chemistry technique (avidin-biotin-peroxidas) was mainly used for the rat 
cochleae and a standard immunofluorescence staining in the human specimen. 
These techniques utilize the antibody-antigen connection principle by using 
an antibody specific for the target protein in question, in this case Proges-
terone receptors A and B and both together (PRA, PRB, PR). In immuno- 
histochemistry, a second antibody chemically linked to peroxidase will bind 
to the first and this step will make it possible to identify the protein by 
staining. In immunofluorescence, the second antibody is labeled by a 
 detectable fluorescent dye.
For the immunohistochemistry, thin sections from dissected, decalcified and 
paraffin imbedded inner ears from twelve rats (six 3-month old females and 
six 12-month old males) and one human specimen were used. They were 
stained with the following antibodies: NCL-PGR312 for PRA, MA1-411 for 
PRB and MA1-410 for PR, according to the routine protocol in the labora-
tory (55). For negative controls the antibody was replaced by non-immune 
serum and tissue from rat and human uteri was used for positive and nega-
tive controls. After being incubated with the second antibody (biotinylated 
horse anti-mouse IgG antibody), followed by horse-radish peroxidase-avidin-
biotin complex a DAB-staining for exposure times from 20-90 s was used 
and then counterstained with hematoxylin. The sections were inspected and 
photographed by using a Zeiss Axioplan microscope connected to a PixieLINK 
camera.
The immunofluorescence staining technique was used for enabling visualiza-
tion of both the PRs and the cell nuclei in the human section. A fresh frozen, 
thin section was incubated with the same primary antibodies as used in the 
rat sections, but as second antibody Alexa 488 (for green fluorescence) and 
DAPI (for blue nuclei fluorescence) were used. Human uteri were used as 
positive and negative controls. The staining was visualized in a Zeiss LSM510 
confocal microscope with appropriate filters and excitation wave-lengths.
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PCR, Polymerase chain reaction
This method was used in study III in the attempt to amplify PRB mRNA from 
the inner ear. The DNA is denaturized by a brief heating and then cooled to 
allow primers to attach to its target sequence after which a DNA polyme-
rase will make a new copy of the mRNA with the use of nucleotides in the 
surrounding liquid. This sequence will be repeated several times to be able 
to multiply even small quantities of mRNA exponentially into measurable 
amounts. The end-product is then controlled by using an agarose gel elec-
trophoresis, size-separating the RNA product and the gel is stained to iden-
tify the result.
Four cochleae from two 3-month old female rats were micro-dissected from 
the surrounding bone and isolated using RNeasy® mini kit. After preparation, 
PCR was performed in a thermal cycler (2720 Thermal cycler) and the PCR 
products were stained with GelRed and analyzed on a 2% agarose gel.
Western blot
This is a third method used in study III in the attempt to identify PRA and PRB 
proteins in the inner ear. By lysing the cells, the proteins are extracted and 
size-separated by gel electrophoresis. With the knowledge of the protein-
size (120 kD for PRB and 80 kD for PRA) the progesterone receptors can be 
identified after antibody binding.
Two one year old rats, in total four cochleae, one from each sex were used. 
The frozen tissue was homogenized in a MagnaLyser separately for the male 
and the female cochleae and the cytosolic fraction was separated. A nuclear 
extraction buffer produced the nuclear fraction after centrifugation. In order 
to ensure the protein-content a BSA-protein assay kit was used showing 20 
µg protein in the cytosolic fraction and 10 µg in the nuclear. The proteins 
were then separated in a NuPAGE 4-10 % Bis-Tris gel and transferred onto a 
polyvinylidene difluoride membrane to enable interaction with the antibody. 
Transfer efficacy was controlled by a MemoCode reversible Protein stain kit. 
To reduce non-specific binding the membrane was placed in a blocker me-
dium (Odyssey blocking buffer) before incubated with PR antibody (MA1-
410). The second antibody (IRDye800- and IRDye680 conjugated secondary 
antibodies) was added before band detection was performed using direct 
infrared fluorescence detection. A rat uterus and GAPDH´40 (an added pro-
tein with the size of 40 kD) served as control.
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Speech and language, cognitive and social skills
All tests regarding speech and language and cognitive skills in the partici-
pants were performed by an experienced Speech and Language therapist in 
regard to their age. Social and pragmatic skills, as well as the participants’ 
mental health, were measured by questionnaires completed by the parents 
of children under the age of 18. The test-battery aimed to recognize any 
specific difficulties in this cohort with cochlear implants due to Pendred syn-
drome or DNFB4.
Speech and language tests
Several tests are regularly used to determine the speech and language level 
and progress for every cochlear implanted child at the Cochlear implant unit. 
This is performed to ensure the improvement and quick detection of a need 
for increased support. Speech and language tests are divided in receptive 
(passive) and expressive (active) knowledge and a deficit in one area or the 
other indicates different causes. A third part is the pragmatic skills test which 
determines the ability to adapt language usage to a social context. All tests 
have their specific age-frames which are the reason the participants were 
tested with different numbers of age appropriate tests.
The Peabody Picture Vocabulary test IV (PPVT IV), a picture identifying test, 
was used from the age of two to examine receptive vocabulary and the 
results were compared to American norms (56). The Boston Naming Test 
(BNT) used from the age of four is a picture naming test, designed to measure 
expressive vocabulary. The Boston Naming Test resulted in a raw score which 
was translated into a stanine compared with Swedish normative data (57). 
For the level of expressive grammar, the in-house scale (Syntax) was used 
with the scores 1-8 where 1 was equal to “no use of voice with intent” and 
8 been equal to “typical or correct expressive grammar and sentence level” 
(58). The Speech and Intelligibility Rating scale 2 (SIR2) evaluates the level 
of understandable speech (59). Finally, the parents answered the Children’s 
Communication Checklist 2 (CCC-2), a questionnaire regarding pragmatic 
skills in children four to fourteen years of age (60). The results were com-
pared with English norms. A Level of spoken language development was 
determined, based on the results of all tests and test-scores within a year 
from age-matched normal hearing individuals were rated as age-equivalent.
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Cognitive tests
Knowledge of the cognitive capabilities of a child is useful in learning situa-
tions in order to adapt the level of difficulty and in choosing exercises. Here 
they are used as screening tools for cognitive deficits. Two different assess-
ments were used. 
Raven colored matrices is a test for non-verbal cognitive ability for children 
four to twelve years of age. The score is transferred to percentiles and com-
pared to English norms (61). A parent and teacher questionnaire, Behavior 
Rating Inventory for Executive Functions (BRIEF), was used for evaluating the 
executive functions from the age of two (62). Test results were compared 
with American norms.
Social skills
Social skills, mental health and speech and language development are 
closely interconnected. There is a risk, especially in children with hearing 
impairment, for speech and language delays which could affect social inte-
raction. In order to screen the participants for social skills and mental health 
issues, the Strength and Difficulties Questionnaire was answered by parents 
and teachers (63). It contains 25 items grouped in five subscales: emotional 
symptoms, conduct problems, hyperactivity-inattention, peer problems and 
prosocial behavior. The score is validated in Swedish as well as for people 
with hearing impairment (64, 65).
Surgery
The 29 patients with LVAS and/or IP2 malformation had had a normal cochle-
ar implant procedure at the Karolinska University Hospital after preopera-
tive investigations regarding speech and language, hearing and vestibular 
function, medical assessment, electrocardiography (ECG) and imaging (MRI 
and/or CT scan). The surgery was performed during general anesthesia by 
a limited mastoidectomy and a posterior tympanotomy to reach the round 
window while preserving the facial nerve and corda tympany (the taste 
nerve). The electrode was then introduced into the Scala tympani via the 
round window, a cochleostomy or, in some cases, an extended round win-
dow procedure. As an extra precaution, nerve monitoring of the facial nerve 
is compulsory during surgery. All patients were given one dose antibiotics 
and cortisone in accordance to their weight during surgery. The patients 
stayed overnight postoperatively and had a plain x-ray for control of electrode 
placement the following day before leaving the hospital.
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Radiology
All available MRI and CT scans were reviewed by an experienced radiologist 
and an ENT surgeon. The x-rays were reexamined for modiolar dysplasia, apex 
dysplasia, asymmetric relation between Scala vestibuli and tympani (Scalar 
asymmetry), vestibular aqueduct enlargement (>1.5 mm), semicircular canal 
anomalies and symmetrical findings between inner ears (figure 4).
Statistics
Non-parametric tests were used in studies I, II and IV due to the small num-
ber of participants and non-normal distribution of variables. Chi2 tests were 
applied to determine a significant difference between two groups regarding 
a dichotomous outcome. For calculations where there were less than five 
individuals in one or more of the possible turn-outs, the Fischers exact test 
was used. The Mann-Whitney U-test compares ordinal data from two inde-
pendent groups. If more than two groups were compared Kruskal Wallis test 
was applied. Binary multiple regression was used in study II for evaluation 
of treatment effect of estrogen substitution, anabolic steroid and growth 
hormone treatment on hearing adjusted for karyotype, spontaneous puber-
ty, and otitis proneness. Significance was regarded as p<0.05 with *<0.05, 
**<0.01 and ***<0.001. All analyses were performed using SPSS version 22.
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RESULTS
Studies I and II
Seventy-seven women with Turner syndrome were identified and 64 (83 
%) were finally included, 35 out of 45 women in the recent group and 29 
out of 32 in the historic group. Fifty-three percent had karyotype 45,X, 14 % 
46,X,i(Xq) and 33 % a mosaics karyotype. The percentages in-between these 
groups differed in the recent and historic cohort but when comparing 45,X 
and 46,X,i(Xq) versus mosaics there was no significant difference between 
cohorts (p=0.796). Collected medical data are presented in table 1.
 
45,X
(%)
46,X,i(Xq)
(%)
Mosaic
(%)
Recent 
(%)
Historic  
(%)
All
(%)
Missing  
(%)
n 34 (53) 9 (14) 21 (33) 35 (55) 29 (45) 64
Mean age 32.3 32.8 32.8 32.4 32.8 32.6
Mean age at detection 8.4 12.0 16.6 7.9 15.1 11.2
Genotyp
   - 45,X 21 (60) 13 (45) 34 (53) 0
   - mosaic 11 (31) 10 (34) 21 (33) 0
   - 46,Xi(Xq) 3 (9) 6 (21) 9 (14) 0
Treatment
   - None 0 (0) 0 (0) 3 (14) 1 (3) 2 (7) 3 (5) 0
   - Estrogen 34 (100) 9 (100) 18 (87) 34 (97) 27 (93) 61 (95) 0
   - Growth hormone 21 (62) 3 (33) 10 (48) 33 (94) 1 (3) 34 (53) 0
   - Anabolic steroids 22 (65) 7 (78) 9 (43) 23 (66) 15 (52) 38 (59) 0
Mean treatment length 
(year)
15.8 15.4 10.7 16.1 12.4 14.1 2 (3)
Mean estrogen score 21.9 22.2 15.2 20.1 19.4 19.8 2 (3)
Spontanous puberty 4 (12) 3 (33) 13 (62) 9 (26) 11 (38) 20 (31) 0
Otitis prone as a child 18 (53) 4 (44) 8 (38) 18 (51) 12 (41) 30 /47) 2 (3)
Otosurgery 4 (12) 2 (22 3 (14) 3 (9) 2 (7) 5 (8) 1 (2)
Hearing aid 6 (18) 1 (11) 0 (0) 3 (20) 5 (17) 8 (11) 2 (3)
Ototoxic substances 0 (0) 1 (11) 0 (0) 0 (0) 1 (3) 1 (2) 30 (47)
Family history of hea-
ring loss
3 (9) 2 (22) 3 (14) 2 (6) 6 (21) 8 (13) 23 (36)
Smoking 3 (9) 0 (0) 3 (14) 0 (0) 6 (21) 6 (9) 8 (13)
Table 2: Collected medical data for all subjects divided in karyotype and cohort respectively.
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Audiologic configuration
In general, women with karyotype 45,X and 46,X,i(Xq) suffered from poorer 
hearing thresholds than the group with mosaic karyotype (p=0.034). There 
was no significant difference between the results for 45,X and 46,X,i(Xq) re-
gardless of type, configuration or grade. Sensorineural hearing loss was the 
type of hearing loss most frequently seen in the participants (45 %) and with 
a predominance in karyotype 45,X and 46,X,i(Xq). They also showed a higher 
percentage of high-frequency sloping and mid-frequency u-shaped configu-
rations. In Figure 8, the mean hearing level divided by degree of hearing 
loss according to HEAR in paper I is presented. The characteristic progress 
in hearing loss from normal hearing with a slight mid- and high-frequency 
dip transforms into a more pronounced mid-frequency dip and mild hea-
ring loss. In the group with moderate hearing loss the progress is worse in 
the high frequencies, resulting in a classical sloping configuration, hiding the 
mid-frequency dip.
Figure 8: Median hearing thresholds per frequency and divided by grade of hearing loss according to 
HEAR (50).
Compared with an otologically unscreened, non-occupationally noise-expo-
sed Swedish population of 337 women between 18-80 years of age, the wo-
men with Turner syndrome (aged 25-38) had a median hearing level, in the 
low and high frequencies, slightly worse than 50-59 year old women in the 
normal population. In the mid-frequencies (b), they resembled 60-69 year 
old women. Divided in grade of hearing loss according to HEAR, the normal 
hearing women with Turner syndrome had a hearing in level comparable to 
50-59 year old women with normal hearing (a).
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Figure 9: Median hearing in normal hearing women with Tuner syndrome (a) and the median hea-
ring level all women with Turner syndrome (b) (all aged 25-38) compared with a Swedish cohort of 
non-occupationally noise-exposed women aged 18-80.
Figure 10: Mean hearing thresholds in women with Turner syndrome with and without GH treat-
ment a), anabolic steroid treatment b), otitis proneness c) and spontaneous puberty d). A statisti-
cally significant difference (*) was found in univariate tests (Mann-Whitney U-test) regarding GH 
treatment at 3-8 kHz, anabolic treatment at 0.125-0.25 and 1-1.5 kHz, otitis proneness at 0.125-
0.5 kHz as well as spontaneous puberty at 3-4 kHz.
Hearing and Endocrine Treatment
There were no correlations of hearing loss per frequency, type of hearing or 
configuration with estrogen treatment regardless of time or dosage. Estro-
gen scores show no correlation, except for a negative association between 
estrogen score and mid-frequency u-shape configuration. Growth hormone 
treatment had a significant negative association with sloping configuration 
and hearing loss in the high frequencies independently of karyotype, oti-
tis media proneness and spontaneous puberty (figure 10). Anabolic steroid 
treatment had a significant positive association with sloping and a positive 
correlation with otitis proneness.
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Cohort and Hearing
A significant difference was identified in the prevalence of normal 
hearing (p=0.036) and risk for sloping configuration (p=0.017) between the 
cohorts with less normal hearing and more sloping configuration in the recent 
cohort. Regarding back-ground factors there were significantly more women 
with growth hormone treatment (p=0.000), estrogen treatment for a longer 
period (p=0.001), but with lower total estrogen score (p=0.024), and fewer 
number of smokers (p=0.007) in the recent cohort.
Hearing aids
Eight women out of 64 (12.5 %) were already rehabilitated with hearing aids 
at the time of inclusion in the study and with a hearing ranging from mild to 
severe according to HEAR (50). Two women had at least one ear with a seve-
re hearing loss and were both fitted with hearing aids, however, only about 
one third of women with moderate hearing loss were fitted. All of them had 
sloping or mid-frequency u-shaped configuration.
Study III
Immunohistochemistry/Immunoflourescence
There was no visible staining of PRA, PRB or PR in the organ of Corti, stria 
vascularis or spiral ganglion in rats or humans after repeated staining. In the 
surrounding cochlear bone, a nuclear staining of both PRB and PR could be 
identified. A weak cytoplasmic staining of PRB in large ganglion cells was 
seen in both paraffin embedded and fresh-frozen human samples but not in 
Figure 11: Immunohistochemistry for progesterone receptor A (PRA) showing no 
nuclear staining in spiral ganglion in human inner ear (A) and a positive nuclear staining in 
endometrial controls (B) but none in negative controls (C). A positive nuclear staining for 
progesterone receptor B (PRB) in surrounding bone (black arrows) in rat inner ear is shown 
in figure D).
41
Hormon effect on the inner ear: two endocrine syndromes
the rat inner ear. A shade of this was noted in human specimens using the 
PR antibody. The positive and negative controls showed a correct nuclear 
staining pattern in regard to their treatment except for PRA in rats were the 
antibody did not show any staining neither in the inner ear nor the endo-
metrial controls, e.g. the PRA antibody was non-functioning. Therefore, we 
used a PR antibody staining both PRA and PRB at the same time, in order to 
investigate if PRA could be present in the inner ear. The results were nega-
tive, showing no nuclear staining in the inner ear.
 
PCR
The PCR was only performed in rat due to a lack of human specimen. There 
was a negative result on the PCR for PRB in the rat organ of Corti, stria vascu-
laris and spiral ganglion confirming the results of the immunohistochemistry.
Western blot
For minimizing protein loss, the whole rat cochlea, as well as bone, was in-
cluded in the Western blot. PRB could be detected in both nuclear and cyto-
plasmic fractions in male and female rats, but there was no detection of PRA. 
This concludes the findings of PRB in the surrounding cochlear bone and a 
lack of PRA in the inner ear.
Study IV
Twenty-nine patients, all of whom underwent cochlear implant surgery as 
children between 1991 and 2016, were included in this study and divided 
in three groups in regard to their hearing history. This was done in an at-
tempt to sort out some of the problems due to a significant difference in 
demographic data regarding age, age at implantation, history of hearing per-
formance, hearing aid use and schooling. This is in part due to historical dif-
ferences in postoperative rehabilitation. One child with a neuropsychiatric 
disorder was excluded from statistical calculations. The definition of groups 
and demographics regarding number, sex, age and hearing history are pre-
sented in table 3. Eighty-six percent used spoken language as their primary 
language and 45 % were fluent in sign language probably reflecting the dif-
ferent historic conditions for children with severe to profound hearing loss 
in Sweden, where sign language was the main language for deaf children 
for decades. Fifty-two percent had bilateral cochlear implants, 7 % had uni-
lateral with one deaf ear and 41 % had bimodal solutions (a hearing aid in 
one ear and a cochlear implant in the other). Forty-one percent attended 
mainstream school and as many as 23 % were or had been attending deaf, 
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signing schools. In the structured medical interview, there were two unex-
pected findings regarding general behavior. Fifty-nine percent of the partici-
pants had or had had sleeping disturbances such as difficulty falling asleep 
or repeatedly waking up at night. Sleeping disturbances were not correlated 
to particularly poor results in speech and language tests. Difficulty concen-
trating was reported by 52 % and this group had significantly lower score on 
the expressive vocabulary tests.
Total Group 1 Group 2 Group 3
Nb 29 8 12 9
Sex (F/M) 13/16 3/5 6/6 4/5
Median age 8.7 (1.8-25.2) 3.7 (1.8-12.1) 9.4 (3.9-25-2) 11.9 (6.9-15.3)
Median age at implant 
    -   first 3.1 (0.4-12.6) 0.9 (0.4-1.9) 3.1 (2.0-6.0) 5.1 (1.8-12.6)
    -   second 2.5 (0.7-13.3) 1.5 (0.7-2.3) 4.1 (2.5-11.0) 12.0 (10.7-13.3)
Congenital deafness 10 (34) 7 (88) 3 (25) 0 (0)
Early progress (<2 years) 8 (28) 1 (12) 6 (50) 1 (11)
Slow progress (>2 years) 11 (38) 0 (0) 3 (25) 8 (89)
Hearing mode
CI + CI 15 (52) 7 (88) 6 (50) 2 (22)
CI + HA 12 (41) 1 (12) 4 (33) 7 (78)
CI + deaf 2 (7) 0 (0) 2 (17) 0 (0)
School 22 3 10 9
    -   mainstream 9 (41) 2 (67) 2 (20) 5 (56)
    -   special unit 8 (36) 0 (0) 4 (40) 4 (44)
    -   deaf school 5 (23) 1 (33) 4 (40) 0 (0)
Language
    -   spoken  language as  
        primary
25 (86) 7 (88) 10 (83) 8 (89)
    -   fluent in sign language 13 (45) 3 (38) 6 (50) 3 (33)
Table 3: Background information regarding hearing history, schooling and language in the 
3 groups and together. Group 1 = congenital or early progressive hearing loss with early 
implantation (<2 years of age). Group 2 = congenital deafness with late implantation (>2 
years of age) and progressive hearing loss with preoperatively unsatisfying hearing aid use. 
Group 3 = children with progressive hearing loss and preoperatively good speech and langu-
age development. One participant in group 1 had a neurodevelopmental disorder and was 
not included in the results of the speech and language tests. The range is added between 
brackets for age and percentage between brackets for hearing history schooling and langu-
age. F = Female, M = Male.
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Surgery and adverse events
In total 46 surgeries were performed including two reoperations, one due to 
tip fold-over of the Nucleus CI532 electrode and one due to a failing implant. 
Due to repeated occasions with tip fold-over or near events also outside the 
study, CI 532 is judged not to be appropriate for implantation in patients with 
LVAS and IP2. Twenty individuals used implants from MedEl and nine from 
Cochlear. A round window insertion was performed in 34 cases without any 
complications regarding insertion. An oozing (mild CSF-leakage from the in-
ner ear) was reported in 21 of 30 (70 %) surgeries but the status was unknown 
in 16 cases. Ten cases had nausea (22 %) and vertigo was seen in five patients 
(11%) after surgery. In all but two cases the postoperative nausea or vertigo 
did not prevent discharge from the ward the day after surgery. No antiemetic 
drugs other than cortisone are given routinely during surgery. One patient 
had to stay another night due to a suspicion of CSF-leakage which was trea-
ted conservatively with bedrest. No CSF leakage could be confirmed.
Radiology
Nb % Missing Group 1
(missing)
Group 2
(missing)
Group 3
(missing)
Aqueduct enlargement 26/26 100 1 7/7 (1) 10/10 9/9
Vestibular enlargement 25/27 93 0 8/8 9/10 8/9
Symmetric malformation 23/26 88 1 7/8 9/10 7/8 (1)
Modiolar dysplasia 22/27 81 0 7/8 8/10 7/9
Apex dysplasia 9/13 69 14 4/5 (3) 3/5 (5) 2/3 (6)
Scalar asymmetry 8/26 31 1 4/8 4/10 0/8 (1)
Semicircular canal anomaly 7/27 26 0 5/8 2/10 0/9
Table 4: The number and percentage of inner ear malformation and the rate of inner ear 
malformation in each group. Group 1 represents congenital or early progressive hearing loss 
with early implantation (<2 years of age). Group 2: congenital deafness with late implanta-
tion (>2 years of age) and progressive hearing loss with preoperatively unsatisfying hearing 
aid use. Group 3 includes children with progressive hearing loss and preoperatively good 
speech and language development.
X-rays from 27 participants were possible to retrieve while three had a CT 
performed only, seven had a MRI only and seventeen had both a CT and 
an MRI. Eighty-nine percent (n=24) of the participants presented with LVAS 
bilaterally, 7 % (n=2) unilaterally and one was indecisive. IP2 malformation 
was present in 81 % (n=22), all bilaterally. Further radiological details are 
presented in table 4. There were no associations between the radiological 
findings and speech and language outcomes. Scalar asymmetry and semi-
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circular canal anomaly were associated with a negative effect on speech re-
cognition in quiet independent of age and were significantly more common 
in group 1 than group 3 (p=0.035, p=0.011).
Hearing
The mean speech recognition scores were 74 % in quiet and 34 % in noise 
with a significantly better result in group 3 (late implanted with history of 
good hearing) than in group 2 (late implanted with insufficient hearing for 
speech and language development) in quiet (p=0.004). There are no signi-
ficant differences between groups regarding speech recognition in noise, 
adaptive HINT or sound localization. Participants with a history of fluctua-
tion in hearing had a significantly higher score on speech recognition in both 
quiet and noise (p=0.003, p=0.046), adaptive HINT (p=0.028), bimodal hea-
ring (0.037) and a higher incidence of sleep disturbances (p=0.005). Only one 
participant out of 13 had a negative speech-to-noise ratio on the adaptive 
HINT test compared with 70 % of normal hearing children aged 6-11 years.
Speech and language
Sixty-one percent had speech and language abilities estimated as age-equi-
valent or better including all in group 3 but less than half in group 2. The 
group presented weak results regarding expressive vocabulary but normal 
results on receptive vocabulary. All results in spoken language abilities were 
significantly correlated with speech recognition in quiet but not in noise 
(p=0.000-0.006). There was a generally low total score in the 19 participants 
who concluded the pragmatic skills questionnaire (CCC-2) with a particularly 
low score on the questions regarding “speech”. Participants attending a spe-
cial unit or deaf school had significantly lower scores on the questions regar-
ding “semantics” (p=0.030) as well as on expressive vocabulary (p=0.043). 
Participants with reported motor problems during childhood had a signifi-
cantly negative effect on the receptive vocabulary test (PPVT) (p=0.009) and 
the expressive vocabulary test (BNT) (p=0.020) when corrected for age.
Cognitive function and social skills
The overall results for executive function, non-cognitive skills and social skills 
were normal. Participants with fluctuation in hearing and hereditary predis-
position for dyslexia had significantly higher scores on emotional problems 
graded by their parents (p=0.012, p=0.007). Participants with hereditary pre-
disposition for dyslexia also had significantly more problems on the parental 
total score and hyperactivity-inattention behavior (p=0.010, p=0.025) but 
this was not supported by the teacher scores which indicated problems at 
home but not in school. 
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DISCUSSION
Hearing in two endocrine syndromes
Endocrine systems have a strong interaction with hearing and the develop-
ment of the inner ear. In Turner syndrome, as in Pendred syndrome and 
DFNB4 there is a vulnerability of the inner ear closely connected with the 
syndrome. Young adults with Turner syndrome already have a hearing situa-
tion on par with women at least twenty year older, in a Swedish cohort, and 
the need for hearing rehabilitation is high from an early age. The estrogen 
substitution does not seem to improve hearing although the combination 
with progesterone might interfere with the results. The pathway for proges-
terone interference on hearing is still unclear since we could not demon-
strate a presence of nuclear progesterone receptors in the inner ear of rat 
and human. Significantly worse hearing in the high frequencies was seen in 
growth hormone treated women but other environmental factors cannot be 
excluded. In Pendred syndrome and DFNB4, a severe to profound hearing 
loss is seen. This hearing loss often has an early onset leading to a need 
for hearing rehabilitation with a cochlear implant. The speech and language 
results show low results in expressive vocabulary and pragmatic skills and 
vertigo, fluctuating hearing, motor problems and sleeping disturbances were 
common.
Hearing in Turner syndrome, Pendred syndrome and DFNB4
In Turner syndrome, the hearing problems are divided in three stages with 
childhood otitis-dependent conductive hearing loss, mid- and/or high-fre-
quency sensorineural hearing loss starting as a mild type in youth and pro-
gressing to mild-severe with age. In study I the rates of conductive (1.6 %) 
and mixed (6.3 %) hearing loss were in the lower range compared to other 
studies in the same age-span where the rate was 3- 8 % for conductive and 
4-24 % for mixed hearing loss (23, 66). This could be due to a lower percen-
tage of otitis proneness (47 %) in the current study. Even though conductive 
and mixed hearing loss was sparse, 52 % of the women had hearing loss in at 
least one ear. The only other study published, by Verver et al, concentrating 
on women in a similar age-span showed a hearing loss in 66 % but that co-
hort had a higher incidence of otitis media and middle ear surgery that might 
explain the difference (66). The most common configurations were high-fre-
quency hearing loss and mid-frequency dip both most frequent among wo-
men with karyotype 45,X and 46,X,i,(Xq). This is in coherence with the results 
from King et al and Beckman et al (23, 67).
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Compared to the mild to moderate, progressive hearing loss in Turner syn-
drome, hearing in Pendred syndrome is regarded as mainly profound, bilate-
ral, and congenital (31, 38, 68, 69). After the introduction of genetic testing, 
the phenotype in Pendred syndrome has started to be questioned due to dif-
ferent penetration within families regarding severity of hearing loss, thyroid 
enlargement, and the results on the perchlorate discharge test (a test of the 
organification of iodine in the thyroid decreased in Pendred syndrome) (68). 
Regarding this, the distinction between cohorts presented in the literature 
with Pendred syndrome, IP2 malformation, Mondini malformation, DFNB4 
and Large Vestibular Aqueduct syndrome is somewhat blurred, obstructing 
the possibility to compare the results. In the cohort of children in study IV, 
10 had a congenital deafness and 19 had progressive hearing loss with 11 
children presenting at least one normal ear in early childhood screening sho-
wing that a majority of hearing loss is not present at birth. Of the five pa-
tients with genetically confirmed Pendred syndrome only one had congenital 
deafness which is a result well representative of the diversity of the subject 
population. A fluctuation in hearing is often a precursor to a progressive hea-
ring loss common in patients with DFNB4. The risk of postponed diagnosis 
of a severe hearing loss due to uncertainty regarding the hearing results in 
children with LVAS and IP2 malformation is an important clinical knowledge.
Anatomical influences on hearing
In Turner syndrome, the lack of the growth-promoting SHOX-gene on the X-
chromosome responsible for the short stature, also affects the development 
of the skull base (15, 17, 25, 70-72). This influences the placement and deve-
lopment of the Eustachian tube that is suggested to be the reason for the in-
creased risk of otitis media and negative middle ear pressure. The incidence 
of otitis media is between 61-82 % and conductive hearing loss is common 
during childhood and adolescence (16, 17, 73). No immunological deficits 
have been determined to be responsible for the increased rate of middle ear 
infection (74). The frequency of tympanic membrane retraction and choles-
teatoma forming is elevated in women with Turner syndrome resulting in the 
need for surgical intervention and a risk for an iatrogenic negative effect on 
hearing (19). 
The hearing loss in Pendred and DFNB4 is related to an inner ear malforma-
tion in contrast to Turner syndrome where the inner ear is usually normally 
configurated (15, 70). Even though a cochlear malformation, in addition to 
LVAS, gives the impression of a more severe malformation Ahadizadeh et al 
could not find any statistically significant difference in hearing between the 
two groups (69). In study IV a relationship between scalar asymmetry and 
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semicircular canal anomaly and speech recognition in quiet was found as 
well as a higher incidence of these malformations in the group with early im-
plantation. This might reflect a relationship between the severity of the mal-
formation, occurrence of congenital deafness and hearing outcome which 
has never before been presented. The numbers are small in the study, and 
further work is needed to show if this is a preoperative, predictive factor 
regarding hearing outcome.
Genetics
Both Turner syndrome and Pendred syndrome/DFNB4 are accompanied by 
a wide spectrum of phenotypes. The degrees of hearing loss, vertigo, tinni-
tus, fluctuating hearing and goiter (Pendred syndrome/DFNB4) differ as do 
the associated characteristics of short stature and autoimmune disorders in 
Turner syndrome. In Turner syndrome the degree of the loss of the X-chro-
mosome is more or less in parallel with the severity of symptoms with 45,X 
having considerably more comorbidities than mosaics as a group (12). On an 
individual level however, the phenotype penetration can vary which is why 
medical advice based on karyotype has to be carefully planned.
In Pendred syndrome and DFNB4 the association with mutations in the 
SLC26A4-gene is strong but differs throughout the world with a higher inci-
dence in Asian than in Caucasian populations (75, 76). The anatomical range 
from an isolated Large Vestibular Aqueduct to an IP2-malformation with or 
without an enlarged thyroid gland necessary for the criteria of Pendred syn-
drome seems not closely associated with karyotype even though homozy-
gote mutations in the SLC26A4-gene have a higher prevalence for Pendred 
syndrome in some studies (75-77). It is suggested that Pendred syndrome 
should be identified as a subtype of a SLC26A4-based syndrome with a spe-
cific pattern of penetrance instead of an isolated syndrome (78). However, 
in both Turner and Pendred syndromes the karyotype alone is not enough 
to explain the phenotype in each individual which is the reason why other 
factors, genetic and environmental, must be considered.
Mouse models
To further study the impact of the genetic characteristics and the genesis of 
the symptoms mouse models of both Turner syndrome and Pendred syn-
drome have been developed. The Turner mouse, 39,X is a strain with growth 
retardation, otitis proneness and early hearing loss in the high frequencies. 
It shows a loss of outer hair cells, most pronounced in the basal turn needed 
for high frequency hearing, and a reduced number of nerve endings con-
necting to the inner hair cells starting at the age of one year (79). The elec-
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tron microscopic imaging also showed lateral wall disintegration as well as a 
swelling in the vascular stria, signs that increase with age. The decrease in 
hearing thresholds in the higher frequencies on ABR followed the visual 
findings. The reason for these findings is yet unknown.
The Pendred knock-out mouse (SLC26A4 null mouse) is profoundly deaf, 
shows a vestibular dysfunction and has an enlargement of the endolymp-
hatic sac and duct as well as a cochlear hydrops (high fluid pressure) (32). 
The mouse model has helped in establishing the function and necessity of 
the Pendrin protein responsible for maintaining the acid-base balance of the 
endolymph. This balance is essential for creating the polarization in the hair 
cells necessary for the neural activity and signaling. A lack of Pendrin creates 
an acidification of the endolymph due to a reduced amount of bicarbonate 
secretion normally used to buffer the proton excess. There is an increased 
oxidative stress in the organ of Corti impairing the expression of KCNJ10 
in the stria vascularis. The KCNJ10-gene is responsible for a potassium- 
regulating channel necessary for the endocochlear potential. An impaired 
expression of the channel explains the inability of the hair cells to produce 
a nerve signal in response to audiological stimuli (8). Pendrin is located both 
in the cochlea and the vestibular organ in the ear, which could explain the 
effect on both hearing and balance. It is also found in the thyroid and 
kidneys.
Hearing rehabilitation
With a hearing loss in the high frequencies as in Turner syndrome, most of 
the fricative consonants (s, tj, f, k) in the Swedish language are lost leading 
to a difficult listening situation. This in combination with a mid-frequency 
dip affecting many of the vowels increases the difficulty identifying words 
(Figure 6). Despite this, only eight women out of 64 in study I used a hearing 
aid while two out of three with moderate hearing loss did not (80). Girls and 
women with Turner syndrome use hearing aids to a higher extent than the 
rest of the population (13, 17, 73), but regarding the results in the study I the 
process of hearing rehabilitation could be more active in order to prevent so-
cial isolation, difficulties at work and increased disability due to hearing (81).
In Pendred syndrome and DFNB4 there is a wide range of hearing loss from 
one-sided moderate to bilaterally profound. This range demands different re-
habilitation solutions, from hearing aids in mild to moderate hearing loss to 
cochlear implants in bilaterally severe to profound hearing loss. The cohort 
presented in study IV is concentrated on children with cochlear implants, a 
subgroup of this diagnosis.
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Cochlear implants in LVAS and IP2-malformation
Cochlear implantation in LVAS and IP2-malformation has been described 
as a safe procedure despite the risk for oozing of cerebrospinal fluid upon 
opening the cochlea (82). In order to prevent continuous leakage and 
meningitis, a tight soft tissue seal should be used around the inserted 
electrode regardless of a round window insertion or a cochleostomy. In 
study IV three children had to stay another night in the hospital due to a 
suspicion of cerebrospinal fluid leakage in one case and severe vertigo in two 
cases. In contrast with the results from Mey et al the presence of oozing/
gusher was common in study IV but did not seem to have a relationship with 
post-operative vertigo. The presentation of the postsurgical vertigo rate is 
sparse in the literature. In the study from Mey et al a postoperative rate of 
vertigo of 22 % was presented, i.e. higher than the 11 % in study IV (83, 84). 
On the other hand no rate of nausea was described in their study, whereas in 
our material some young children with vertigo might have been classified as 
suffering from nausea. In two studies of 300 and 475 non-malformed pe-
diatric cochlear implant patients respectively, only two children were re-
ported to have had postoperative vertigo showing that this complication in 
children without malformation is unusual (85, 86). The risk of vertigo after 
surgery is increased thus the patient and parents should be informed of the 
risk. Further examination of the results in search for possible prognostic pre-
operative factors will be performed.
Speech and language results 
The general conclusion in study IV showing normal results on the receptive 
vocabulary test, but surprisingly low results on the expressive vocabulary 
and pragmatic skills tests that is not previously reported. In the literature 
regarding children with LVAS with or without IP2-malformation and cochle-
ar implantation, there are few reported results on speech and language 
tests and the diversity of tests used are extensive, preventing a comparison 
between studies. Pritchett et al compared isolated LVAS with children with 
LVAS and IP2-malformation showing a non-significant advantage for the iso-
lated LVAS group (87). Regarding hearing tests, Ahadizadeh et al have shown 
the same difference with worse, but not statistically significant results for the 
LVAS and IP2-malformation group, although the groups were small in both 
studies (69). The lack of a control-group in our study prevents comparison 
with other cochlear implanted children at our clinic. However ongoing stu-
dies will improve this matter in the near future. 
Speech and language acquisition depends on several factors where hearing, 
attention and concentration, social skills, and motor performance all are im-
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portant parts. The cohort in study IV presented a lower median score on 
speech recognition in quiet compared with other studies regarding children 
with the same malformation (69, 88, 89). This might mirror the high grade 
of attendance to deaf, signing schools and special units where sign language 
is being used to varying degrees. Only 49 % were integrated in mainstream 
schools and 50 % were fluent sign language users, thus bilingual. Multiling-
ual, normal hearing children show the same pattern with lower results on 
expressive vocabulary, but normal on receptive vocabulary, a fact possibly 
explained by the reduced exposure to each language with less repetition 
(90). Neither sleeping disturbances nor fluctuating hearing had a negative 
effect on vocabulary or pragmatic skills in our material.
A heredity predisposition for dyslexia and parent-reported difficulties with 
concentration were associated with a sub pathologic score on hyperactivity-
inattention. Parent-reported difficulty to concentrate was also associated 
with lower scores on the expressive vocabulary and pragmatic skills tests. No 
child was diagnosed with dyslexia or hyperactivity disease, e.g. ADHD, to our 
knowledge. Hearing impairment might lead to difficulties with concentration 
and hyperactivity, but the high frequencies of these problems in this study 
are intriguing and needs further investigation. Meanwhile, establishing a 
personalized speech, and language learning environment is crucial.
Motor performance is an important factor in early communication develop-
ment. The ability to correspond to facial expressions, as well as interact with 
others, is dependent on mobility and the possibility to focus on interaction 
instead of movement (91). A possible competition between the focus on mo-
tor activity and hearing is also possible. In participants reporting childhood 
motor problems an association with decreased results in speech and langu-
age outcome was seen and is to our knowledge not reported elsewhere. This 
indicates a necessity to screen for motor problems and assure appropriate 
intervention, when needed, in order to improve the possibilities for the best 
hearing outcome. Further analysis regarding vestibular function and motor 
skills are currently ongoing in an attempt to verify these findings.
Hormonal treatment and hearing
Most articles in the literature show an overview of several periods in the 
lives of women with Turner syndrome. The present studies (studies I and II) 
concentrate on hearing in early adulthood focusing on hearing during that 
period of life and the evaluation of long term follow up after medical treat-
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ment. There is a significant difference in hearing between the recent and 
historic cohorts showing a decrease in hearing thresholds over time with a 
reduction in the number of normal hearing individuals as well as a higher risk 
for sloping configuration. This can be due to an inclusion bias caused by a 
higher rate of normal hearing women in the historic cohort while the normal 
hearing individuals in the recent cohort chose not to participate in the study. 
Normal hearing individuals are less likely to have been tested regardless of 
timeframe why this should reduce the risk for bias. There is a overrepresen-
tation of women with karyotype 45,X in the recent cohort compared with 
the historic cohort, however the relationship between karyotype 45,X and 
46,X,i(Xq) versus mosaic karyotype is comparable in the two cohorts. In the 
literature, a general decrease in hearing among the younger population in 
Sweden has been found, especially in women, and the reason for this is not 
known (1). There can therefore be a general cause for worse hearing in the 
recent cohort but changes in treatment, cohort composition or combina-
tions of these are other options. 
Estrogen
The reason for hearing loss in Turner syndrome is yet unknown but one of 
the theories is based on the lack of estrogen. Estrogen receptors have been 
mapped in the inner ear (92, 93) and in the central auditory pathways (46) 
and mice lacking the estrogen receptor beta become deaf within a year  of 
age (42). Women have quite stable hearing up until the age of menopause 
in comparison with men whose hearing starts to decline already around the 
age of 30 (39, 40). This is thought to be due to a protective effect of estrogen. 
In women with Turner syndrome, with an insufficient endogenous produc-
tion of estrogen, the hearing decline starts early.
The cohorts in study II show differences in hormonal treatment with a 
shorter period of estrogen treatment, but at higher doses in the historic 
cohort compared to the recent cohort, and growth hormone treatment 
almost exclusively in the recent cohort. The difference in estrogen treatment 
did not show any significant association with hearing in multiple regression 
analysis except for a negative association between estrogen score and the 
presence of a mid-frequency dip. This result was regarded as non-specific 
due to the small cohort size since neither the length nor amount of estrogen 
treatment showed equal results and the result of the multiple regression 
model was not significant. The progesterone portion of the treatment could 
have an interfering impact on the hearing result and will be discussed further 
on.
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Estrogen substitution does not start until the time for induction of puberty 
around the age of 12 and it is arguable that this is too late for hearing pre-
servation. In a recently published study by Ros et al hearing in three cohorts, 
women with Turner syndrome, women with congenital hypogonadism due 
to other reasons and women with normal estrogen production, was compa-
red (94). All groups were treated with combined hormonal replacement th-
erapy. The women with congenital hypogonadism due to a cause other than 
Turner syndrome had hearing in level with women with normal estrogen 
levels (20 % vs 27 %) while the women with Turner syndrome had a higher 
percentage of individuals with hearing loss (87 %) indicating a minor role for 
estrogen as a cause of hearing loss. There was however a 60 % rate of spon-
taneous puberty in the cohort with congenital hypogonadism compared to 
20 % in the Turner cohort thus the groups are not comparable in regard to 
estrogen deficiency.
Another theory put forward is the Cell cycle delay hypothesis based on a de-
ficiency in the SHOX-gene situated on the short arm of the X-chromosome. 
This gene is necessary for the normal development of the otic capsule in a 
dose-dependent manner (25). This together with a generally longer cell cycle 
for abnormal cell lines, as 45,X, could lead to a lower density of sensory hair 
cells in the inner ear causing a higher sensitivity for hair cell loss that could 
explain the findings in the inner ear of the Turner mouse(25, 79).
Growth hormone
There was a significant negative association between growth hormone 
treatment and sloping configuration (high-frequency hearing loss) in study II. 
A worse PTA4 in a growth hormone treated group of women with Turner syn-
drome compared with a non-treated group has been published in the litera-
ture (23), but the reason for non-treatment was not accounted for why. This 
could be dependent on karyotype or other factors known to interfere with 
hearing. In the present study, all women were treated with growth hormone 
regardless of karyotype after the introduction of the new guidelines, except 
two individuals who were identified too late for treatment. The relationship 
between the two karyotypes with the highest frequency of hearing loss (45,X 
and 46,X,i(Xq)) and the mosaic karyotypes were equal in the recent and his-
toric groups reducing the risk for interference on hearing due to karyotype. 
Growth hormone and its metabolite IGF-1 are necessary for cell prolifera-
tion, cochlear ganglion maturation and regulation of cochlear development 
(95). In syndromes associated with IGF-1 deficiency hearing loss is a com-
mon but not mandatory. Symptoms range from normal hearing to profound 
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hearing loss (96). There is a correlation between a low concentration of 
IGF-1 in blood and a higher risk for hearing loss as well as otitis proneness 
in women with Turner syndrome (25). There is also a negative association 
between intrauterine growth retardation and a short final statue and 
sensorineural hearing loss in men (97). All these findings show the impor-
tance of growth hormone and IGF-1 in hearing and cochlear development. 
The relation between excessive growth hormone and hearing is less well 
described. Individuals with acromegaly (98) and McCune-Albright syndro-
me (99) have an increased risk for hearing loss that can be mixed, sensori- 
neural or conductive. The genesis of this can be due to the excess of growth 
hormone but other contributing factors cannot be excluded. In conclusion, 
there is sparse support in the literature regarding a possible negative 
effect of growth hormone treatment on hearing loss. Other factors may affect 
these findings and further research is needed.
Progesterone
It is arguable that study II did not exclusively investigate the effect of estro-
gen on hearing in Turner women given that the therapy most often used 
is a combination of estrogen and progesterone. There are studies showing 
a negative effect of progesterone on hearing as part of Hormone Replace-
ment Therapy in menopausal women where both pure-tone testing, DPOAE 
(Distorsion Product OtoAucoustic Emissions) and hearing in noise tests were 
worse in combined treatment groups as compared to estrogen treatment 
alone (48, 100). Although there are indications of an effect of progesterone 
on the inner ear the pathway is yet unknown.
Experimental studies
Immunohistochemistry is a non-quantitative measure and problems can be 
encountered at various levels. The inner ear is a challenging organ due to 
its composition of delicate soft tissue enclosed by the densest bone in the 
body. The decalcification procedure, the antigen-retrieval and the specificity 
and sensitivity of the antibodies can all interfere with the results. Insuffi-
cient blockage of non-specific proteins can cause background staining and 
an obscuring of the results. The antibodies used in study III had all been 
successfully used before in different tissues. Regardless, the PRA antibody 
did not show any staining neither in rats nor in humans on both the test and 
control samples. The reason for this is unknown and adjustments in the test-
procedure with additional washing and adjusted denaturation processes did 
not change the outcome. In order to ensure coverage of the PRA-receptor 
with the immunohistochemistry method the PR antibody with an affinity to 
both receptor A and receptor B was used as well. 
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PCR and Western blot are quite robust methods, but they are sensitive to 
impurities in the sample and it is important to have a good amount of the 
protein to measure. In PCR, the primer needs to be specific enough to bind 
only to the DNA selected for amplification but short enough to be efficient. 
If the primer reacts with other parts of the DNA the output will be non-
specific and if it is too long the number of amplifications will be reduced and 
the result might be falsely negative. For Western blot as for Immunohisto-
chemistry the specificity and sensitivity of the antibodies are important as 
are the characteristics of the gel. In a gel with a bigger pore size the proteins 
will travel faster and vice versa which necessitates that it is chosen in regard 
to the protein of interest.
In study III, no nuclear receptors in the organ of Corti, stria vascularis or spiral 
ganglion were found either by immunohistochemistry or PCR. In Western 
blot PRB receptors were found and the immunohistochemistry confirmed 
the presence of nuclear PRB in the surrounding bone. The lack of PRA in the 
Western blot confirmed the lack of PR staining in the rat inner ear’s immu-
nohistochemistry. All the results were coherent for male and female rats as 
well as humans including the different ages in rat.
Other possible pathways
Regarding the negative effect of progestin treatment on hearing, the impact 
is probably mediated via other pathways. Progesterone has both nuclear re-
ceptors, transmembrane receptors as well as membrane-associated recep-
tors, the last two acting via signaling cascades at the cell membrane level 
(101). No mapping of the latter two has been made in the inner ear thus 
their existence is unknown. Progesterone is also a known antagonist to the 
mineralocorticoid and corticoid receptors preventing their activities. These 
receptors are known to be present in the inner ear, both in stria vascularis, 
where they are responsible for the ion hemostasis, and in the hair cells (102-
104). Progesterone has an especially high affinity to the mineralocorticoid 
receptor; a receptor used by corticosteroids and, above all, the mineralo-
corticoid aldosterone. Aldosterone regulates the potassium balance in the 
body and interacts with the ion homeostasis in the inner ear necessary for 
depolarization of the hair cells. In the aging human, the concentration of 
aldosterone normally decreases and a correlation between low serum aldos-
terone levels and a higher incidence of high frequency hearing loss has been 
observed. Aldosterone substitution in a mouse model showed a protective 
effect on hearing due to a blocking effect of apoptotic pathways improving 
the cell survival in the spiral ganglion cells, particularly in the basal turn of 
the cochlea (105). Treatment with progesterone containing medication could 
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inhibit the effect of aldosterone thus increasing the risk for high-frequency 
hearing loss.
Thyroid hormones
Thyroid hormones are crucial for the early neuromotor development as well 
as for the development of the inner ear (106). In congenital hypothyroidism, 
early treatment with thyroid hormone substitution will reduce the risk for 
severe hearing impairment as well as the negative effect on mental, motor, 
language and cognitive development (107). There are three known thyroid 
receptors, one thyroid receptor alpha and two thyroid receptor beta (1 and 
2). Mouse models deficient in the different thyroid receptor beta receptors 
show different responses. In thyroid receptor beta 1 deficient mice a pro-
found hearing loss is developed whereas the hearing seems to stay intact in 
thyroid receptor beta 2 deficient mice (108, 109). In Pendred syndrome the 
thyroid hormone levels are within normal limits in at least 50 % of the indivi-
duals, but some develop a hypothyroidism in need for substitution (31, 38). 
The Pendrin protein is involved in the organification of iodine in the thyroid 
gland, however it is not the sole anion exchanger responsible for this process 
(34). The reduced expression of Pendrin in SLC26A4 mutations can lead to a 
deficit, or subclinical deficit, in thyroid hormone levels that might interfere 
with the neuromotor development, possibly contributing to the associated 
symptoms regarding behavior, motor development and language acquisition 
seen in study IV. Further research regarding the effect of a subclinical thyroid 
hormone deficiency on neuromotor development is needed.
 
Limitations
The retrospective character of the studies on women with Turner syndrome 
always has its limitations regarding the possibility to retrieve information 
from the charts and uncertainty regarding accuracy in treatment-time, co-
verage of participants and medical issues. The possible negative interference 
of the progesterone compound in the estrogen treatment might affect the 
results regarding hearing. Further measures to calculate the progesterone 
portion could possibly have clarified the hormonal effect on hearing. Howe-
ver, the effects of progesterone on hearing, as well as the pathway, are not 
clear; therefore the possibility to estimate the effect of different compounds 
would be difficult.
In the aim to cover both sexes and a wide age-range, male and female rats 
(3, 6 and 12 months of age) were used although with different methods 
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leaving a possibility of a changing receptor activity in different sexes and 
ages. Additional Western blot tests with a dissected cochlea and at different 
ages would have ensured the lack of progesterone receptors in the inner 
ear with higher accuracy. Nevertheless, the consistency of the experiments, 
throughout both sexes and ages, strengthens the findings.
In the study of cochlear implants in children with LVAS and/or IP2 malforma-
tion one important weakness is the lack of genetic confirmation of Pendred 
syndrome and DFNB4. This leaves a possibility of including participants with 
other syndromes where these malformations are present. All participants 
except one have ongoing genetic testing, thus future work on this cohort will 
include these results. 
The decision to include all patients with LVAS and/or IP2 malformation 
having received a cochlear implant as children leads to a diverse group 
regarding age at time for testing as well as their representation of 
different rehabilitation schemes over the years. The children operated in the 
90-ties and early 2000 had sign language education to a higher extent than 
children operated today. A between subject difference also exists in regard to 
regional traditions in postoperative rehabilitation. The addition of a control 
group would also have strengthened the study. 
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FURTHER PERSPECTIVES
- The effect on hearing by the progesterone portion in combined 
contraceptives needs to be investigated to exclude an additional 
reason for the worse hearing in the recent cohort
- To understand the negative effect of progesterone on hearing, 
mapping of the progesterone receptors in the central auditory pathway 
as well as membrane receptors and indirect pathways are essential.
- Further insight in vestibular and balance function in children with LVAS 
and IP2 and its relationship to hearing and speech as well as language 
outcome would be an important contribution for the improvement of 
the rehabilitation in these children.
- Sleep disturbances are common in children with LVAS and IP2 and 
significantly impact family life. Further investigation of sleep-pattern, 
presence of obstructive sleep apnea and the impact on family life 
would improve the possibilities for preventive programs to assist in the 
improvement of sleep patterns.
- Further investigation of the presence and frequency of radiological 
findings, particularly scalar asymmetry and semicircular canal ano-
maly, in LVAS with IP2 malformation and its relationship to the 
outcome and genetics.
- The rate of and predictive factors for adverse events after cochlear 
implantation in patients with Pendred and DFNB4 need to be further 
evaluated.
- The relationship between the significantly poor results in speech and 
language development in children with parent-reported concentra-
tion difficulties needs further investigation in order to enhance the 
support in language acquisition. A possible link to brain development 
in Pendred syndrome has to be further investigated.
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CONCLUSIONS
1. Study I: Sensorineural hearing loss is common in young adults with 
Turner syndrome and the two most frequent types of hearing 
loss are mid-frequency u-shaped and high frequency hearing loss. 
Hearing in young women with Turner syndrome deteriorates 
early and is devastating for the listening situation. Young women with 
Turner syndrome would benefit from a more active hearing rehabili- 
tation regimen. It is important with an implementation of a continuous 
control of the hearing as well as early contact with counselling. Reha-
bilitation, when needed, should begin as early as possible in order to 
ensure the possibility for social well-being and active participation in 
the working environment. 
2. Study II: Estrogen treatment does not seem to have any positive 
effect on hearing, but the progesterone content might interfere with 
the results. An association with high frequency hearing loss in growth-
hormone treated women has been detected and may reflect a nega-
tive effect on hearing by growth hormone treatment.
3. Study III: There is no direct effect of progesterone via nuclear proges-
terone receptors in the organ of Corti, stria vascularis or spiral gangli-
on but Progesterone receptor B is present in the surrounding cochlear 
bone. The progesterone effect is probably mediated through other 
pathways, the transmembrane-bound, membrane associated proges-
terone receptors, mineralocorticoid- or glucocorticoid receptors.
4. Study IV: Children with Pendred syndrome and DFNB4 deafness with 
LVAS and IP2 malformation are a complex group with weak results on 
expressive vocabulary and pragmatic skills tests. A history of affected 
motor skills and parent-reported concentration difficulties seems to be 
a risk factor which explains why it is important to screen for these dif-
ficulties. Semicircular canal anomalies and Scalar asymmetry might be 
a preoperative predictor for a worse outcome.
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POPULÄRVETENSKAPLIG SVENSK SAMMANFATTNING
Omkring 5 % av världens befolkning är drabbad av hörselnedsättning som 
påverkar deras vardag enligt WHO. Vid många endokrina syndrom finns även 
en påverkan på hörsel och vid både Turner syndrom och Pendred syndrom är 
hörselrehabiliterande åtgärder med hörapparat respektive cochleaimplantat 
vanligt förekommande. Man har även sett effekter av hormonell behandling 
på hörseln där progesteroninnehållande hormonbehandling i menopaus har 
associerats med sämre hörsel.
Målet med denna avhandling är att belysa förhållandet mellan hörsel och 
endokrinologin både genom studier av endokrina syndrom samt genom att 
undersöka vägar för direkt hormonell påverkan på innerörat.
I studie I och II har hörseln hos unga kvinnor med Turner syndrom studerats 
samt östrogen-, tillväxthormon- och anabola steroid-behandlingens even- 
tuella effekt på hörseln studerats. Sensorineural hörselnedsättning, fram-
förallt i form av försämrad hörsel i diskanten och i mellanregistret, är de 
vanligast förekommande hörselkonfigurationerna. Grad av hörselnedsättning 
är oftast mild till måttlig och leder till behov av hörselrehabilitering med hör- 
apparat i större utsträckning än för normalbefolkningen. Ingen effekt kunde 
ses på hörseln av östrogenbehandling men en försämrad diskanthörsel sågs 
i gruppen behandlad med tillväxthormon.
I studie III kartlades förekomsten av progesteron receptor A och B i innerörat 
på råtta och människa i avsikt att identifiera en möjlig väg för direkt påverkan 
av progesteron på innerörat och hörseln. Inga progesteron receptorer kunde 
identifieras i hörselbildande strukturer i innerörat vid immunohistokemi, 
PCR eller Western blot. Dock påträffades Progesteron receptor B i snäckans 
omgivande ben.
I studie IV kartlades den preoperativa hörselutvecklingen hos barn och unga 
med cochleaimplantat och Pendreds syndrom eller DFNB4 med inneröremiss-
bildning i form av LVAS och/eller IP2. Även det hörselmässiga och språkliga 
resultatet utvärderades. En stor bredd i den preoperativa hörselutvecklingen 
sågs från kongenital dövhet till en långsamt progressiv hörselnedsättning, 
ofta med fluktuerande inslag. Språkmässigt hade deltagarna normalt passivt 
ordförråd men nedsatt aktivt ordförråd samt pragmatisk förmåga. En förhöjd 
andel av deltagarna hade även yrsel, fluktuerande hörsel, påverkad motorisk 
utveckling, nedsatt koncentrationsförmåga samt sömnstörningar.
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Sammanfattningsvis så är hörselnedsättning ett vanligt problem i samhället 
och är inte sällan kopplat till endokrina syndrom, t.ex. Turner syndrom och 
Pendred syndrom. Båda dessa syndrom kan leda till grav hörselnedsättning 
även om kongenital dövhet endast är förknippat med Pendred syndrom. 
Tidiga rehabiliterande insatser med hörapparat eller cochleaimplantat be-
roende på hörselnedsättning är nödvändig för att motverka social isolering 
samt gagna språkinlärning och taluppfattning. Hormonell behandling kan ha 
en påverkan på hörseln men effekten av progesteron sker troligen via andra 
vägar än direkt via nukleära receptorer i innerörat.
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